Edition:
India

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

11.07USD
21 Sep 2018
Change (% chg)

$-0.08 (-0.72%)
Prev Close
$11.15
Open
$11.10
Day's High
$11.10
Day's Low
$10.83
Volume
9,457
Avg. Vol
19,816
52-wk High
$20.12
52-wk Low
$8.23

Latest Key Developments (Source: Significant Developments)

Clementia Pharmaceuticals Reports Qtrly Loss Per Share Of $0.34
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.34.  Full Article

Clementia Appoints Steve Forte As Chief Financial Officer
Friday, 13 Jul 2018 

July 13 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA APPOINTS EXPERIENCED FINANCIAL EXECUTIVE STEVE FORTE AS CHIEF FINANCIAL OFFICER.CLEMENTIA PHARMACEUTICALS INC - APPOINTMENT OF STEVE FORTE, AS CHIEF FINANCIAL OFFICER, EFFECTIVE AUGUST 3, 2018.CLEMENTIA PHARMACEUTICALS INC - FORTE WILL REPLACE CURRENT CFO, MICHAEL SINGER, WHO WILL TRANSITION FROM HIS ROLE EFFECTIVE AUGUST 9, 2018.  Full Article

Clementia's Treatment With Palovarotene Significantly Reduces New Bone Growth In Patients With FOP
Wednesday, 23 May 2018 

May 23 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA REPORTS POSITIVE PHASE 2 PART B DATA SHOWING TREATMENT WITH PALOVAROTENE SIGNIFICANTLY REDUCES NEW BONE GROWTH IN PATIENTS WITH FOP.PHASE 2 PART B DATA SHOW EVALUABLE PATIENTS WITH NO NEW BONE AT 12 WEEKS HAD NO NEW BONE AT 12 MONTHS.STATISTICALLY SIGNIFICANT 91% REDUCTION OF NEW HO AT FLARE-UP SITES AT 12 WEEKS; 65% REDUCTION OF NEW HO AT 12-MONTH WBCT SCAN IN PHASE 2 DATA.PALOVAROTENE GENERALLY WELL-TOLERATED IN TRIAL, CONSISTENT WITH EXPERIENCE ACROSS PALOVAROTENE CLINICAL STUDIES.RECENTLY SURPASSED ENROLLMENT OF FIRST 35 PATIENTS IN OUR PHASE 3 MOVE TRIAL, ON TRACK TO COMPLETE STUDY ENROLLMENT BY YEAR END.ON TRACK TO REPORT FIRST INTERIM ANALYSIS FOR MOVE TRIAL IN MID-2019.  Full Article

Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.CLEMENTIA PHARMACEUTICALS INC - COMPLETION OF ENROLLMENT FOR PHASE 3 MOVE TRIAL EXPECTED BY END OF 2018.  Full Article

Clementia Pharmaceuticals qtrly loss per share ‍$1.83​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Clementia Pharmaceuticals Inc ::Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​.Clementia Pharmaceuticals Inc- ‍as of September 30, 2017, had cash and investments of $152.2 million​.Clementia - ‍anticipates reporting preliminary results from part b open-label extension portion of phase ii study of palovarotene in fop in Q2 2018​.Clementia Pharmaceuticals Inc- on track to begin move study protocol phase iii study and enroll first patient by end of 2017​.  Full Article